G9P/CD158D Antibody (YA7099)(PBS only)
(Synonyms: CD158d, CD158D, KIR103AS, KIR2DL4, Killer cell immunoglobulin-like receptor 2DL4, CD158 antigen-like family member D, G9P, Killer cell inhibitory receptor 103AS, MHC class I NK cell receptor KIR103AS, KIR-103AS)G9P/CD158D Antibody (YA7099) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to G9P/CD158D.
-
Host:
Mouse
-
Isotype:
IgG1
-
Application:
FC, ELISA
-
Reactivity :
Human
-
Formulation:
Supplied in PBS, pH 7.4.
-
Conjugation:
Non-conjugated
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
Applications
| Application |
FC
FC: Flow Cytometry
|
ELISA
ELISA: Enzyme Linked Immunosorbent Assay
|
|---|---|---|
| Dilution Ratio | 1:200-1:400 | 1:10000 |
Product Details
G9P/CD158D Antibody (YA7099) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to G9P/CD158D.
-
Host Mouse
-
Species ReactivityHuman
-
Calculated Molecular Weight Predicted band size: 41.5kDa;
Purified recombinant fragment of human CD158D (AA: extra 22-120) expressed in E. Coli.
affinity purified.
Non-conjugated
IgG1
Product Properties
-
Appearance
Solution
-
Formulation
Supplied in PBS, pH 7.4.
-
Storage & Stability
Stored at -20°C for 1 year. Avoid repeated freeze / thaw cycles.
-
Shipping
Shipping with blue ice.
Background
-
Function
G9P/CD158D receptor for non-classical major histocompatibility class Ib HLA-G molecules. Recognizes HLA-G in complex with B2M/beta-2 microglobulin and a nonamer self-peptide (peptide-bound HLA-G-B2M). In decidual NK cells, binds peptide-bound HLA-G-B2M complex and triggers NK cell senescence-associated secretory phenotype as a molecular switch to promote vascular remodeling and fetal growth in early pregnancy. May play a role in balancing tolerance and antiviral-immunity at maternal-fetal interface by keeping in check the effector functions of NK, CD8+ T cells and B cells. Upon interaction with peptide-bound HLA-G-B2M, initiates signaling from the endosomal compartment leading to downstream activation of PRKDC-XRCC5 and AKT1, and ultimately triggering NF-kappa-B-dependent pro-inflammatory response[1][2][3][4][5].
-
Subcellular Localization
Cell membrane,Early endosome membrane
-
Expression
Tissue_Specificity: Expressed in decidual NK cells and innate lymphoid cell type I (ILC1) (PubMed:29262349). Expressed in a subset of peripheral NK cells (PubMed:19304799) -
Isoforms & Post-Translational Modification
Q99706 has 6 isomers: Q99706-1: 41487 Da (predicted); Q99706-2: 39699 Da (predicted); Q99706-3: 37356 Da (predicted); Q99706-4: 35568 Da (predicted); Q99706-5: 33591 Da (predicted); Q99706-6: 24917 Da (predicted).
-
Subunit
Interacts with peptide-bound HLA-G-B2M heterotrimeric complex (PubMed:10190900, PubMed:16366734)
-
SwissProt ID
-
Synonyms
CD158d, CD158D, KIR103AS, KIR2DL4, Killer cell immunoglobulin-like receptor 2DL4, CD158 antigen-like family member D, G9P, Killer cell inhibitory receptor 103AS, MHC class I NK cell receptor KIR103AS, KIR-103AS
Documentation
Powered by Bioz
